Zydus Launches India's First Indigenously Developed Aflibercept 2 mg Biosimilar ANYRA™

Zydus Lifesciences Ltd., an innovation-led global life sciences company, announced the launch of Anyra™, India’s first indigenously developed biosimilar of Aflibercept 2 mg. The biosimilar is indicated for the treatment of various ophthalmic conditions including neovascular (wet) Age-related Macular Degeneration (AMD), visual impairment due to macular edema secondary to Retinal Vein Occlusion (Branch RVO or Central RVO), visual impairment due to Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and visual impairment due to Myopic Choroidal Neovascularization (mCNV). This launch reinforces Zydus' commitment to advancing ophthalmic care and expanding access to high-quality, affordable biologics for patients across India. With over 100 million people in India living with diabetes, the biosimilar is expected to improve treatment adherence, reduce preventable blindness, and lower long-term disease burden.